Scarica l'app Stockscreener
6.77
1.02%
-0.07
Dopo l'orario di chiusura:
6.80
0.03
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.84
Aprire:
$6.74
Volume 24 ore:
444.24K
Relative Volume:
0.37
Capitalizzazione di mercato:
$192.36M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-5.8362
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
+10.44%
1M Prestazione:
-9.13%
6M Prestazione:
-50.94%
1 anno Prestazione:
-64.27%
Intervallo 1D:
$6.6258
$6.87
Intervallo di 1 settimana:
$6.11
$6.99
Portata 52W:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
6.77 | 194.35M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | Downgrade | Citigroup | Buy → Neutral |
| 2025-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-28 | Iniziato | BTIG Research | Buy |
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessPortfolio Profit Report & Precise Entry and Exit Recommendations - ulpravda.ru
Is Arcturus Therapeutics Holdings Inc. stock positioned well for digital economyJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - ulpravda.ru
mRNA drug developer Arcturus to share its work at major health conference - Stock Titan
Earnings Beat: Can Arcturus Therapeutics Holdings Inc. stock rebound after recent weaknessWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
Arcturus Therapeutics Holdings (ARCT): Analyst Ratings Suggest a Staggering 415% Upside Potential - DirectorsTalk Interviews
(ARCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
UK Regulator OKs Arcturus Therapeutics' COVID-19 Booster Jab - marketscreener.com
What analysts say about Arcturus Therapeutics Holdings Inc stockStraddle and Strangle Trades & Investment Case Studies - earlytimes.in
Arcturus Therapeutics Holdings files for mixed shelf of up to $500 millionSEC filing - MarketScreener
Arcturus Therapeutics Files $500 Million Mixed Shelf - MarketScreener
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics (ARCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will Arcturus Therapeutics Holdings Inc. stock benefit from infrastructure spending2025 Volume Leaders & Risk Controlled Daily Trade Plans - Улправда
How strong is Arcturus Therapeutics Holdings Inc. stock balance sheetMarket Activity Report & Weekly Watchlist of Top Performers - Улправда
How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataTrade Risk Assessment & Weekly High Return Stock Forecasts - Улправда
Why Arcturus Therapeutics Holdings Inc. stock could outperform in 2025Weekly Market Report & Daily Momentum Trading Reports - DonanımHaber
How supply chain issues affect Arcturus Therapeutics Holdings Inc. stockWeekly Trend Recap & AI Enhanced Market Trend Forecasts - DonanımHaber
Arcturus Therapeutics Holdings Inc. Announces Management Changes - marketscreener.com
Arcturus Therapeutics CFO Andy Sassine to leave company - marketscreener.com
Arcturus Therapeutics announces CFO transition and interim appointment By Investing.com - Investing.com Australia
Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks
Arcturus Therapeutics announces CFO departure and replacement - MSN
Arcturus Therapeutics announces CFO transition and interim appointment - Investing.com
Arcturus Therapeutics Announces CFO Departure and Interim Appointment - TradingView — Track All Markets
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Institution Moves: How buyback programs support Comerica Incorporated Depositary Shares each stockJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - moha.gov.vn
Retail Surge: How interest rate cuts could boost Arcturus Therapeutics Holdings Inc stock 1; waitfor delay '0:0:15' - moha.gov.vn
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know - MSN
Can Arcturus Therapeutics Holdings Inc. stock hit analyst price targetsJuly 2025 Outlook & Weekly Top Gainers Alerts - Newser
How Arcturus Therapeutics Holdings Inc. stock trades before earningsJuly 2025 Recap & AI Powered Buy and Sell Recommendations - Newser
(ARCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
Guidance Update: How Arcturus Therapeutics Holdings Inc. stock reacts to job market dataNew Guidance & Safe Entry Momentum Stock Tips - moha.gov.vn
Wells Fargo Maintains Arcturus Therapeutics Holdings (ARCT) Overweight Recommendation - MSN
Will Arcturus Therapeutics Holdings Inc. stock deliver shareholder valueJobs Report & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Form 8-KCurrent report - ADVFN
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conference - MarketScreener
User | sweetwaterreporter.comArcturus Therapeutics to Attend Upcoming Investor Conference - FinancialContent
Arcturus Therapeutics Hits 52-Week Low at $6.02 Amid Major Decline - Markets Mojo
Arcturus Therapeutics Hits 52-Week Low at $5.85 Amid Financial Struggles - Markets Mojo
Responsive Playbooks and the ARCT Inflection - Stock Traders Daily
What drives Arcturus Therapeutics Holdings Inc stock priceLow Beta Stocks & Free Trend Following Techniques - earlytimes.in
Is Arcturus Therapeutics Holdings Inc. stock a safe haven assetJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - newser.com
Balyasny Asset Management L.P. Increases Stake in Arcturus Thera - GuruFocus
Is Arcturus Therapeutics Holdings Inc. stock ready for a breakoutJuly 2025 Review & Technical Buy Zone Confirmation - newser.com
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):